# PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

| | |
|---|---|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | SECURITY AGREEMENT |

CONVEYING PARTY DATA

| Name | Execution Date |
|---|---|
| Supernus Pharmaceuticals, Inc. | 05/03/2013 |

RECEIVING PARTY DATA

| | |
|---|---|
| Name: | U.S. Bank National Association |
| Street Address: | Corporate Trust Services |
| Internal Address: | One Federal Street, 3rd Floor |
| City: | Boston |
| State/Country: | MASSACHUSETTS |
| Postal Code: | 02110 |

PROPERTY NUMBERS Total: 54

| Property Type | Number |
|---|---|
| Patent Number: | 6287599 |
| Patent Number: | 6811794 |
| Patent Number: | 7011846 |
| Patent Number: | 6890918 |
| Patent Number: | 6793934 |
| Patent Number: | 6110498 |
| Patent Number: | 6361796 |
| Patent Number: | 6514532 |
| Patent Number: | 6284276 |
| Patent Number: | 6814979 |
| Patent Number: | 6838093 |
| Patent Number: | 7910128 |
| Patent Number: | 7259153 |
| Patent Number: | 7022337 |

CH $2160.00 6287599

| | |
|---|---|
| Patent Number: | 7300794 |
| Patent Number: | 6772801 |
| Patent Number: | 7611728 |
| Patent Number: | 8193211 |
| Patent Number: | 7722898 |
| Patent Number: | 7910131 |
| Patent Number: | 8017149 |
| Patent Number: | 8211464 |
| Patent Number: | 8298576 |
| Patent Number: | 8298580 |
| Patent Number: | 6897212 |
| Patent Number: | 6613763 |
| Application Number: | 12929238 |
| Application Number: | 10435597 |
| Application Number: | 10980819 |
| Application Number: | 10995942 |
| Application Number: | 13476369 |
| Application Number: | 11250309 |
| Application Number: | 11412100 |
| Application Number: | 13476337 |
| Application Number: | 13595103 |
| Application Number: | 12926936 |
| Application Number: | 11987806 |
| Application Number: | 11779562 |
| Application Number: | 12654455 |
| Application Number: | 13318007 |
| Application Number: | 12436954 |
| Application Number: | 12478979 |
| Application Number: | 12585157 |
| Application Number: | 13512706 |
| Application Number: | 11897940 |
| Application Number: | 13075607 |
| Application Number: | 13638294 |
| Application Number: | 13084612 |
| Application Number: | 12477665 |

| | |
|---|---|
| | 13761757 |
| Application Number: | 61701007 |
| Application Number: | 13834097 |
| Application Number: | 61725883 |
| Application Number: | 61727570 |

CORRESPONDENCE DATA

Fax Number: 2159724156
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*
Phone: 2159727755
Email: patents@saul.com
Correspondent Name: Gregory S. Bernabeo, Esq.
Address Line 1: Centre Square West, 1500 Market Street
Address Line 2: 38th Floor
Address Line 4: Philadelphia, PENNSYLVANIA 19102

| | |
|---|---|
| ATTORNEY DOCKET NUMBER: | 103535.00035 |
| NAME OF SUBMITTER: | Gregory S. Bernabeo |
| Signature: | /Gregory S. Bernabeo/ |
| Date: | 06/07/2013 |

Total Attachments: 17
source=Supernus Patent Security Agreement#page1.tif
source=Supernus Patent Security Agreement#page2.tif
source=Supernus Patent Security Agreement#page3.tif
source=Supernus Patent Security Agreement#page4.tif
source=Supernus Patent Security Agreement#page5.tif
source=Supernus Patent Security Agreement#page6.tif
source=Supernus Patent Security Agreement#page7.tif
source=Supernus Patent Security Agreement#page8.tif
source=Supernus Patent Security Agreement#page9.tif
source=Supernus Patent Security Agreement#page10.tif
source=Supernus Patent Security Agreement#page11.tif
source=Supernus Patent Security Agreement#page12.tif
source=Supernus Patent Security Agreement#page13.tif
source=Supernus Patent Security Agreement#page14.tif
source=Supernus Patent Security Agreement#page15.tif
source=Supernus Patent Security Agreement#page16.tif
source=Supernus Patent Security Agreement#page17.tif

# PATENT SECURITY AGREEMENT

This **PATENT SECURITY AGREEMENT** (this "**Patent Security Agreement**") is made this 3rd day of May, 2013, by and among the Grantor listed on the signature pages hereof (the "**Grantor**"), and **U.S. BANK NATIONAL ASSOCIATION**, in its capacity as collateral agent for the Secured Parties (in such capacity, together with its successors and assigns in such capacity, "**Collateral Agent**").

## WITNESSETH:

**WHEREAS**, pursuant to the Indenture, dated as of May 3, 2013 among the Grantor and U.S. Bank National Association, a national banking association, as Trustee and Collateral Agent (as it may be amended, supplemented, extended, renewed, replaced, refunded or modified from time to time, the "**Indenture**"), **SUPERNUS PHARMACEUTICALS, INC.**, a Delaware corporation, (the "**Company**"), has issued to the Holders (as defined in the Indenture) the 7.50% Convertible Senior Secured Notes due 2019 (the "**Notes**"). Grantor is entering into this Patent Security Agreement in order to induce the Holders (as defined in the Indenture) to purchase the Notes and to secure the Secured Obligations;

**WHEREAS**, the Collateral Agent is willing to enter into the Indenture and the Holders are willing to purchase the Notes, but only upon the condition, among others, that Grantor shall have executed and delivered to Collateral Agent, for the benefit of the Secured Parties, that certain Security and Pledge Agreement, dated as of May 3, 2013 (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the "**Security and Pledge Agreement**"); and

**WHEREAS**, pursuant to the Security and Pledge Agreement, Grantor is required to execute and deliver to Collateral Agent, for the benefit of the Secured Parties, this Patent Security Agreement;

**NOW, THEREFORE**, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantor hereby agrees as follows:

1. DEFINED TERMS. All initially capitalized terms used but not otherwise defined herein have the meanings given to them in the Security and Pledge Agreement or, if not defined therein, in the Indenture.

2. GRANT OF SECURITY INTEREST IN PATENT COLLATERAL. Grantor hereby unconditionally grants to Collateral Agent, for the benefit of each of the Secured Parties, to secure the Secured Obligations, a continuing security interest (referred to in this Patent Security Agreement as the "**Security Interest**") in all of such Grantor's right, title and interest in and to the following, whether now owned or hereafter acquired or arising (collectively, the "**Patent Collateral**"):

(a) all of its Patents and Patent Intellectual Property Licenses to which it is a party including those referred to on Schedule I;

(b) all divisionals, continuations, continuations-in-part, reissues, reexaminations, or extensions of the foregoing; and

(c) all products and proceeds of the foregoing, including any claim by Grantor against third parties for past, present or future infringement of any Patent or any Patent exclusively licensed under any Intellectual Property License, including the right to receive damages, or right to receive license fees, royalties, and other compensation under any Patent Intellectual Property License.

3. SECURITY FOR SECURED OBLIGATIONS. This Patent Security Agreement and the Security Interest created hereby secures the payment and performance of the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Patent Security Agreement secures the payment of all amounts which constitute part of the Secured Obligations and would be owed by Grantor to Collateral Agent, the Secured Parties or any of them, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving Grantor.

4. SECURITY AND PLEDGE AGREEMENT. The Security Interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interests granted to Collateral Agent, for the benefit of the Secured Parties, pursuant to the Security and Pledge Agreement. Grantor hereby acknowledges and affirms that the rights and remedies of Collateral Agent with respect to the Security Interest in the Patent Collateral made and granted hereby are more fully set forth in the Security and Pledge Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent there is any inconsistency between this Patent Security Agreement and the Security and Pledge Agreement, the Security and Pledge Agreement shall control.

5. AUTHORIZATION TO SUPPLEMENT. If Grantor shall obtain rights to any new patent application or issued patent or become entitled to the benefit of any patent application or patent for any divisional, continuation, continuation-in-part, reissue, or reexamination of any existing patent or patent application, the provisions of this Patent Security Agreement shall automatically apply thereto. Without limiting the Grantor's obligations under the Note Documents, Grantor hereby authorizes Collateral Agent to unilaterally modify this Patent Security Agreement by amending Schedule I to include any new patent rights of Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Collateral Agent's continuing security interest in all Collateral, whether or not listed on Schedule I.

6. COUNTERPARTS. This Patent Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Patent Security Agreement. Delivery of an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Patent Security Agreement. Any party delivering an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Patent Security Agreement but the failure to deliver an

original executed counterpart shall not affect the validity, enforceability, and binding effect of this Patent Security Agreement.

7. CONSTRUCTION. This Patent Security Agreement is a Note Document. Unless the context of this Patent Security Agreement clearly requires otherwise, references to the plural include the singular, references to the singular include the plural, the terms "includes" and "including" are not limiting, and the term "or" has, except where otherwise indicated, the inclusive meaning represented by the phrase "and/or". The words "hereof", "herein", "hereby", "hereunder", and similar terms in this Patent Security Agreement refer to this Patent Security Agreement as a whole and not to any particular provision of this Patent Security Agreement. Section, subsection, clause, schedule, and exhibit references herein are to this Patent Security Agreement unless otherwise specified. Any reference in this Patent Security Agreement to any agreement, instrument, or document shall include all alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions, joinders, and supplements, thereto and thereof, as applicable (subject to any restrictions on such alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions, joinders, and supplements set forth herein). The words "asset" and "property" shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts, and contract rights. Any reference herein to the satisfaction, repayment, or payment in full of the Secured Obligations shall mean the repayment in full in cash of all Secured Obligations other than unasserted contingent indemnification Secured Obligations. Any reference herein to any Person shall be construed to include such Person's successors and assigns. Any requirement of a writing contained herein shall be satisfied by the transmission of a Record.

8. **THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. GRANTOR AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT IT MAY HAVE TO TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.**

9. **Grantor (i) agrees that any suit, action or proceeding against it arising out of or relating to this Agreement may be instituted in any U.S. federal court with applicable subject matter jurisdiction sitting in The City of New York; (ii) waives, to the fullest extent permitted by applicable law, any objection which it may now or hereafter have to the laying of venue of any such suit, action or proceeding, and any claim that any suit, action or proceeding in such a court has been brought in an inconvenient forum; and (iii) submits to the non-exclusive jurisdiction of such courts in any suit, action or proceeding.**

[*signature page follows*]

**IN WITNESS WHEREOF**, the parties hereto have caused this Patent Security Agreement to be executed and delivered as of the day and year first above written.

**GRANTORS:**

**SUPERNUS PHARMACEUTICALS, INC.**, as Company

By: Gregory S Patrick

Name: Gregory S Patrick

Title: Vice President + Chief Financial Officer

*[Signature Page to Patent Security Agreement]*

**COLLATERAL AGENT:**

**U.S. BANK NATIONAL ASSOCIATION**, as Collateral Agent

By: _____

Name: Alison D B. Nadeau

Title: Vice President

[*Signature Page to Patent Security Agreement*]

# SCHEDULE I
# TO
# PATENT SECURITY AGREEMENT

## Patents

| Grantor | Country | Patent | Application/ Patent No. | Filing Date |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | US | Sustained release pharmaceutical dosage forms with minimized PH dependent dissolution profiles | 6,287,599 | 12/20/2000 |
| Supernus Pharmaceuticals, Inc. | US | Sustained release pharmaceutical dosage forms with minimized PH dependent dissolution profiles | 6,811,794 | 12/20/2001 |
| Supernus Pharmaceuticals, Inc. | US | Oral capsule formulation with increased physical stability | 7,011,846 | 12/20/2002 |
| Supernus Pharmaceuticals, Inc. | US | Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers | 6,890,918 | 04/30/2002 |
| Supernus Pharmaceuticals, Inc. | US | Solid oral dosage form | 6,793,934 | 12/08/1999 |
| Supernus Pharmaceuticals, Inc. | US | Soluble form osmotic dose delivery system | 6,110,498 | 10/22/1997 |
| Supernus Pharmaceuticals, Inc. | US | Soluble form osmotic dose delivery system | 6,361,796 | 08/09/2000 |
| Supernus Pharmaceuticals, Inc. | US | Soluble form osmotic dose delivery system | 6,514,532 | 12/28/2001 |
| Supernus Pharmaceuticals, Inc. | US | Soluble form osmotic dose delivery system | 6,284,276 | 07/11/2000 |
| Supernus Pharmaceuticals, Inc. | US | Soluble form osmotic dose delivery system | 6,814,979 | 12/20/2002 |
| Supernus Pharmaceuticals, Inc. | US | System for osmotic delivery of pharmaceutically active agents | 6,838,093 | 06/01/2001 |
| Supernus Pharmaceuticals, Inc. | US | Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics | 7,910,128 | 01/05/2004 |
| Supernus Pharmaceuticals, Inc. | US | Drug formulation and delivery using crystalline methylated cyclodextrins | 7259153 | 02/02/2004 |
| Supernus Pharmaceuticals, Inc. | US | Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect | 7,022,337 | 06/27/2003 |
| Supernus Pharmaceuticals, Inc. | US | Accelerated culture system for intestinal epithelial cell monolayers | 7,300,794 | 03/11/2004 |
| Supernus Pharmaceuticals, Inc. | US | Fluidization of particles for encapsulation in oral dosage pharmaceutical products | 6,772,801 | 05/14/2003 |
| Supernus Pharmaceuticals, Inc. | US | Osmotic delivery of therapeutic compounds by solubility enhancement | 7,611,728 | 09/05/2003 |

| Grantor | Country | Patent | Application/ Patent No. | Filing Date |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | US | Controlled release compositions of gamma-hydroxybutyrate | 8,193,211 | 09/30/2005 |
| Supernus Pharmaceuticals, Inc. | US | Modified release preparations containing oxcarbazepine and derivatives thereof | 7,722,898 | 04/13/2007 |
| Supernus Pharmaceuticals, Inc. | US | Method of treating seizures using modified release formulations of oxcarbazepine | 7,910,131 | 08/27/2008 |
| Supernus Pharmaceuticals, Inc. | US | Modified release preparations containing oxcarbazepine and derivatives thereof | 8,017,149 | 08/27/2008 |
| Supernus Pharmaceuticals, Inc. | US | Modified release preparations containing oxcarbazepine and derivatives thereof | 8211464 | 08/10/2011 |
| Supernus Pharmaceuticals, Inc. | US | Sustained-release formulations of topiramate | 8,298,576 | 11/16/2007 |
| Supernus Pharmaceuticals, Inc. | US | Sustained-release formulations of topiramate | 8,298,580 | 12/17/2010 |
| Supernus Pharmaceuticals, Inc. | US | Treatment of oppositional defiant disorder and conduct disorder with 5-aminoalkyl-4,5,6,7-tetrahydro-4-oxyindolones | 6,897,212 | 05/07/2003 |
| Supernus Pharmaceuticals, Inc. | US | Use of molindone to treat oppositional defiant disorder and conduct disorder | 6,613,763 | 04/19/2002 |
| Supernus Pharmaceuticals, Inc. | CA | Sustained release pharmaceutical dosage forms with minimized PH dependent dissolution profiles | 2,432,178 | 12/20/2001 |
| Supernus Pharmaceuticals, Inc. | JP | Sustained release pharmaceutical dosage forms with minimized PH dependent dissolution profiles | 4340840 | 12/20/2001 |
| Supernus Pharmaceuticals, Inc. | AU | Sustained release pharmaceutical dosage forms with minimized PH dependent dissolution profiles | 2002249881 | 12/20/2001 |
| Supernus Pharmaceuticals, Inc. | EP | Oral capsule formulation with increased physical stability | 1455763 | 12/20/2002 |
| Supernus Pharmaceuticals, Inc. | CA | Oral capsule formulation with increased physical stability | 2,466,868 | 12/20/2002 |
| Supernus Pharmaceuticals, Inc. | AU | Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers | 2002308494 | 04/30/2002 |
| Supernus Pharmaceuticals, Inc. | EP | Pharmaceutical formulations with improved bioavailability | 1499300 | 04/29/2003 |

| Grantor | Country | Patent | Application/ Patent No. | Filing Date |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | CA | Pharmaceutical formulations with improved bioavailability | 2,483,827 | 04/29/2003 |
| Supernus Pharmaceuticals, Inc. | AU | Soluble form osmotic dose delivery system | 721653 | 10/22/1997 |
| Supernus Pharmaceuticals, Inc. | AU | Soluble form osmotic dose delivery system | 759001 | 10/13/2000 |
| Supernus Pharmaceuticals, Inc. | CA | Soluble form osmotic dose delivery system | 2,269,707 | 10/22/1997 |
| Supernus Pharmaceuticals, Inc. | EP | Soluble form osmotic dose delivery system | 0954291 | 10/22/1997 |
| Supernus Pharmaceuticals, Inc. | MX | Soluble form osmotic dose delivery system | 215656 | 10/22/1997 |
| Supernus Pharmaceuticals, Inc. | JP | Soluble form osmotic dose delivery system | 4863534 | 10/22/1997 |
| Supernus Pharmaceuticals, Inc. | EP | System for osmotic delivery of pharmaceutically active agents | 1392241 | 05/30/2002 |
| Supernus Pharmaceuticals, Inc. | CA | System for osmotic delivery of pharmaceutically active agents | 2,446,712 | 05/30/2002 |
| Supernus Pharmaceuticals, Inc. | JP | System for osmotic delivery of pharmaceutically active agents | 4979180 | 05/30/2002 |
| Supernus Pharmaceuticals, Inc. | AU | System for osmotic delivery of pharmaceutically active agents | 2002303897 | 05/30/2002 |
| Supernus Pharmaceuticals, Inc. | CA | Drug formulation and delivery using crystalline methylated cyclodextrins | 2,514,878 | 02/02/2004 |
| Supernus Pharmaceuticals, Inc. | CA | Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect | 2,490,157 | 06/27/2003 |
| Supernus Pharmaceuticals, Inc. | JP | Drug formulations having reduced abuse potential | 4779082 | 05/12/2004 |
| Supernus Pharmaceuticals, Inc. | CA | Fluidization of particles for encapsulation in oral dosage pharmaceutical products | 2,521,559 | 05/12/2004 |

| Grantor | Country | Patent | Application/ Patent No. | Filing Date |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | JP | Osmotic delivery of therapeutic compounds by solubility enhancement | 4752069 | 09/07/2004 |
| Supernus Pharmaceuticals, Inc. | CA | Compositions of quarternary ammonium compounds containing bioavailability enhancers | 2,536,401 | 11/04/2004 |
| Supernus Pharmaceuticals, Inc. | JP | Compositions of quarternary ammonium compounds containing bioavailability enhancers | 4771956 | 11/04/2004 |
| Supernus Pharmaceuticals, Inc. | AU | Compositions of quarternary ammonium containing bioavailability enhancers | 2004289222 | 11/04/2004 |
| Supernus Pharmaceuticals, Inc. | MX | Compositions of quarternary ammonium compounds containing bioavailability enhancers | 264390 | 11/04/2004 |
| Supernus Pharmaceuticals, Inc. | CA | Micellar systems useful for delivery of lipophilic or hydrophobic compounds | 2,537,029 | 11/24/2004 |
| Supernus Pharmaceuticals, Inc. | JP | Micellar systems useful for delivery of lipophilic or hydrophobic compounds | 4994039 | 11/24/2004 |
| Supernus Pharmaceuticals, Inc. | CA | Less abusable pharmaceutical preparations | 2,581,002 | 10/14/2005 |
| Supernus Pharmaceuticals, Inc. | JP | Less abusable pharmaceutical preparations | 5046946 | 10/14/2005 |
| Supernus Pharmaceuticals, Inc. | AU | Less abusable pharmaceutical preparations | 2005295482 | 10/14/2005 |
| Supernus Pharmaceuticals, Inc. | EP | Osmotic drug delivery system comprising release enhancing agent | 2010189 | 04/26/2007 |
| Supernus Pharmaceuticals, Inc. | EP | An osmotic drug delivery system | 2368556 | 04/26/2007 |
| Supernus Pharmaceuticals, Inc. | EP | Controlled release preparations of oxcarbazepine having sigmoidal release profile | 2026815 | 04/13/2007 |
| Supernus Pharmaceuticals, Inc. | CA | Modified release preparations containing oxcarbazepine and derivatives thereof | 2,597,740 | 04/13/2007 |
| Supernus Pharmaceuticals, Inc. | MX | Controlled release preparations of oxcarbazepine having sigmoidal release profile | 287810 | 04/13/2007 |

| Grantor | Country | Patent | Application/ Patent No. | Filing Date |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | AU | Controlled release preparations of oxcarbazepine having a sigmoidal release profile | 2007242984 | 04/13/2007 |
| Supernus Pharmaceuticals, Inc. | EP | Controlled release preparations of oxcarbazepine having sigmoidal release profile | 2359830 | 04/13/2007 |
| Supernus Pharmaceuticals, Inc. | EP | Sustained-release formulations of topiramate | 1973528 | 11/16/2007 |
| Supernus Pharmaceuticals, Inc. | AU | Sustained-release formulations of topiramate | 2007319141 | 11/16/2007 |
| Supernus Pharmaceuticals, Inc. | EP | Enhanced immediate release formulations of topiramate | 2061431 | 12/04/2007 |
| Supernus Pharmaceuticals, Inc. | US | Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics | 12/929,238 | 01/10/2011 |
| Supernus Pharmaceuticals, Inc. | US | Drug formulations having reduced abuse potential | 10/435,597 | 05/12/2003 |
| Supernus Pharmaceuticals, Inc. | US | Compositions of quarternary ammonium compounds containing bioavailability enhancers | 10/980,819 | 11/04/2004 |
| Supernus Pharmaceuticals, Inc. | US | Micellar systems useful for delivery of lipophilic or hydrophobic compounds | 10/995,942 | 11/24/2004 |
| Supernus Pharmaceuticals, Inc. | US | Controlled release compositions of gamma-hydroybutyrate | 13/476,369 | 05/21/2012 |
| Supernus Pharmaceuticals, Inc. | US | Less abusable pharmaceutical preparations | 11/250,309 | 10/14/2005 |
| Supernus Pharmaceuticals, Inc. | US | An osmotic drug delivery system | 11/412,100 | 04/27/2006 |
| Supernus Pharmaceuticals, Inc. | US | Modified release preparations containing oxcarbazepine and derivatives thereof | 13/476,337 | 05/21/2012 |
| Supernus Pharmaceuticals, Inc. | US | Sustained release formulations of topiramate | 13/595,103 | 08/27/2012 |
| Supernus Pharmaceuticals, Inc. | US | Sustained release formulations of topiramate | 12/926,936 | 12/17/2010 |
| Supernus Pharmaceuticals, Inc. | US | Enhanced immediate release formulations of topiramate | 11/987,806 | 12/04/2007 |
| Supernus Pharmaceuticals, Inc. | US | Enhanced formulations of lamotrigine | 11/779,562 | 07/18/2007 |
| Supernus Pharmaceuticals, Inc. | US | Method of treatment of aggression | 12/654,455 | 12/18/2009 |
| Supernus Pharmaceuticals, Inc. | US | Method of treatment of depression | 13/318,007 | 04/29/2010 |
| Supernus Pharmaceuticals, Inc. | US | Controlled release formulations of alprazolam | 12/436,954 | 05/07/2009 |

| Grantor | Country | Patent | Application/ Patent No. | Filing Date |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | US | Controlled release formulations of pramipexole | 12/478,979 | 06/05/2009 |
| Supernus Pharmaceuticals, Inc. | US | Method of treatment of attention deficit/hyperactivity disorder (ADHD) | 12/585,157 | 09/04/2009 |
| Supernus Pharmaceuticals, Inc. | US | Method of treatment of CNS Disorders | 13/512,706 | 12/02/2010 |
| Supernus Pharmaceuticals, Inc. | US | Topiramate compositions and methods of enhancing its bioavailability | 11/897,940 | 08/31/2007 |
| Supernus Pharmaceuticals, Inc. | US | Stabilized formulations of CNS compounds | 13/075,607 | 03/30/2011 |
| Supernus Pharmaceuticals, Inc. | US | Formulations of mazindol | 13/638,294 | 03/30/2011 |
| Supernus Pharmaceuticals, Inc. | US | Methods of producing viloxazine salts and novel polymorphs thereof | 13/084,612 | 04/12/2011 |
| Supernus Pharmaceuticals, Inc. | US | Use of isoindoles for the treatment of neurobehavioral disorders | 12/477,665 | 06/03/2009 |
| Supernus Pharmaceuticals, Inc. | US | Formulations of viloxazine | 13/761,757 | 02/07/2013 |
| Supernus Pharmaceuticals, Inc. | US | Methods of producing molindone and its salts | 61/701,007 | 09/14/2012 |
| Supernus Pharmaceuticals, Inc. | US | Methods of producing molindone and its salts | 13/834,097 | 03/15/2013 |
| Supernus Pharmaceuticals, Inc. | US | Method of treating aggression | 61/725,883 | 11/13/2012 |
| Supernus Pharmaceuticals, Inc. | US | Method of treating aggression | 61/727,570 | 11/16/2012 |
| Supernus Pharmaceuticals, Inc. | EP | Sustained release pharmaceutical dosage forms with minimized PH dependent dissolution profiles | 01998126.5 | 12/20/2001 |
| Supernus Pharmaceuticals, Inc. | EP | Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics | 04700220.9 | 01/05/2004 |
| Supernus Pharmaceuticals, Inc. | CA | Two or more enteric materials to regulate drug release | 2,514,879 | 01/05/2004 |
| Supernus Pharmaceuticals, Inc. | EP | Drug formulations having reduced abuse potential | 04751878.2 | 05/12/2004 |
| Supernus Pharmaceuticals, Inc. | CA | Drug formulations having reduced abuse potential | 2,525,111 | 05/12/2004 |
| Supernus Pharmaceuticals, Inc. | EP | Drug formulations having reduced abuse potential | 12169706.4 | 05/12/2004 |
| Supernus Pharmaceuticals, Inc. | EP | Osmotic delivery of therapeutic compounds by solubility enhancement | 04783203.5 | 09/07/2004 |

| Grantor | Country | Patent | Application/ Patent No. | Filing Date |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | CA | Osmotic delivery of therapeutic compounds by solubility enhancement | 2,535,060 | 09/07/2004 |
| Supernus Pharmaceuticals, Inc. | EP | Compositions of quaternary ammonium containing bioavailability enhancers | 04800568.0 | 11/04/2004 |
| Supernus Pharmaceuticals, Inc. | HK | Compositions of quaternary ammonium containing bioavailability enhancers | 06109158.3 | 11/04/2004 |
| Supernus Pharmaceuticals, Inc. | IN | Compositions of quaternary ammonium containing bioavailability enhancers | 1946/CHENP/2006 | 11/04/2004 |
| Supernus Pharmaceuticals, Inc. | EP | Micellar systems useful for delivery of lipophilic or hydrophobic compounds | 04812147.9 | 11/24/2004 |
| Supernus Pharmaceuticals, Inc. | EP | Less abusable pharmaceutical preparations | 05808388.2 | 10/14/2005 |
| Supernus Pharmaceuticals, Inc. | CA | An osmotic drug delivery system | 2,649,243 | 04/26/2007 |
| Supernus Pharmaceuticals, Inc. | JP | An osmotic drug delivery system | 2009-507767 | 04/26/2007 |
| Supernus Pharmaceuticals, Inc. | IN | An osmotic drug delivery system | 9177/DELNP/2008 | 04/26/2007 |
| Supernus Pharmaceuticals, Inc. | CN | An osmotic drug delivery system | 200780019545.5 | 04/26/2007 |
| Supernus Pharmaceuticals, Inc. | KR | An osmotic drug delivery system | 10-2008-7028877 | 04/26/2007 |
| Supernus Pharmaceuticals, Inc. | JP | An osmotic drug delivery system | 2013-053126 | 04/26/2007 |
| Supernus Pharmaceuticals, Inc. | JP | Controlled release preparations of oxcarbazepine having sigmoidal release profile | 2009-507891 | 04/13/2007 |
| Supernus Pharmaceuticals, Inc. | CN | Controlled release preparations of oxcarbazepine having sigmoidal release profile | 200780021787.8 | 04/13/2007 |
| Supernus Pharmaceuticals, Inc. | IN | Controlled release preparations of oxcarbazepine having sigmoidal release profile | 4354/KOLNP/2008 | 04/13/2007 |

| Grantor | Country | Patent | Application/ Patent No. | Filing Date |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | JP | Controlled release preparations of oxcarbazepine having sigmoidal release profile | 2012-279022 | 12/21/2012 |
| Supernus Pharmaceuticals, Inc. | AU | Controlled release preparations of oxcarbazepine having sigmoidal release profile | 2013200237 | 01/17/2013 |
| Supernus Pharmaceuticals, Inc. | CA | Sustained-release formulations of topiramate | 2,618,240 | 11/16/2007 |
| Supernus Pharmaceuticals, Inc. | JP | Sustained-release formulations of topiramate | 2009-537388 | 11/16/2007 |
| Supernus Pharmaceuticals, Inc. | MX | Sustained-release formulations of topiramate | MX/a/2009/001 711 | 11/16/2007 |
| Supernus Pharmaceuticals, Inc. | EP | Sustained-release formulations of topiramate | 11179776.7 | 11/16/2007 |
| Supernus Pharmaceuticals, Inc. | CA | Enhanced immediate release formulations of topiramate | 2,658,521 | 12/04/2007 |
| Supernus Pharmaceuticals, Inc. | JP | Enhanced immediate release formulations of topiramate | 2009-539541 | 12/04/2007 |
| Supernus Pharmaceuticals, Inc. | MX | Enhanced immediate release formulations of topiramate | MX/a/2009/003 911 | 12/04/2007 |
| Supernus Pharmaceuticals, Inc. | AU | Enhanced immediate release formulations of topiramate | 2007329373 | 12/04/2007 |
| Supernus Pharmaceuticals, Inc. | CN | Enhanced immediate release formulations of topiramate | 200780032735. 0 | 12/04/2007 |
| Supernus Pharmaceuticals, Inc. | IN | Enhanced immediate release formulations of topiramate | 1228/MUMNP/ 2009 | 12/04/2007 |
| Supernus Pharmaceuticals, Inc. | CN | Enhanced immediate release formulations of topiramate | 201110041776. 4 | 12/04/2007 |
| Supernus Pharmaceuticals, Inc. | EP | Enhanced formulations of lamotrigine | 07016160.9 | 08/17/2007 |
| Supernus Pharmaceuticals, Inc. | CA | Enhanced formulations of lamotrigine | 2,598,948 | 07/31/2007 |
| Supernus Pharmaceuticals, Inc. | JP | Enhanced formulations of lamotrigine | 2010-516966 | 07/31/2007 |
| Supernus Pharmaceuticals, Inc. | MX | Enhanced formulations of lamotrigine | MX/a/2009/011 712 | 07/31/2007 |
| Supernus Pharmaceuticals, Inc. | AU | Enhanced formulations of lamotrigine | 2007356528 | 07/31/2007 |
| Supernus Pharmaceuticals, Inc. | CN | Enhanced formulations of lamotrigine | 200780100437. 0 | 07/31/2007 |

| Grantor | Country | Patent | Application/ Patent No. | Filing Date |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | IN | Enhanced formulations of lamotrigine | 528/DELNP/2010 | 07/31/2007 |
| Supernus Pharmaceuticals, Inc. | CA | Method of treatment of aggression | 2,746,509 | 12/18/2009 |
| Supernus Pharmaceuticals, Inc. | EP | Method of treatment of aggression | 09837980.3 | 12/18/2009 |
| Supernus Pharmaceuticals, Inc. | AU | Method of treatment of aggression | 2009335709 | 12/18/2009 |
| Supernus Pharmaceuticals, Inc. | JP | Method of treatment of aggression | 2011-542480 | 12/18/2009 |
| Supernus Pharmaceuticals, Inc. | MX | Method of treatment of aggression | MX/a/2011/006463 | 12/18/2009 |
| Supernus Pharmaceuticals, Inc. | CA | Method of treatment of depression | 2,760,527 | 04/29/2010 |
| Supernus Pharmaceuticals, Inc. | MX | Method of treatment of depression | MX/a/2011/011579 | 04/29/2010 |
| Supernus Pharmaceuticals, Inc. | JP | Method of treatment of depression | 2012-508732 | 04/29/2010 |
| Supernus Pharmaceuticals, Inc. | BR | Method of treatment of depression | 018110042349 | 04/29/2010 |
| Supernus Pharmaceuticals, Inc. | CO | Method of treatment of depression | 11-165136 | 04/29/2010 |
| Supernus Pharmaceuticals, Inc. | AU | Method of treatment of depression | 2010242971 | 04/29/2010 |
| Supernus Pharmaceuticals, Inc. | CA | Controlled release formulations of alprazolam | 2,722,905 | 05/07/2009 |
| Supernus Pharmaceuticals, Inc. | EP | Controlled release formulations of alprazolam | 09743054.0 | 05/07/2009 |
| Supernus Pharmaceuticals, Inc. | CA | Controlled release formulations of pramipexole | 2,725,482 | 06/05/2009 |
| Supernus Pharmaceuticals, Inc. | EP | Controlled release formulations of pramipexole | 09763332.5 | 06/05/2009 |
| Supernus Pharmaceuticals, Inc. | CA | Method of treatment of attention deficit/hyperactivity disorder (ADHD) | 2,735,934 | 09/04/2009 |
| Supernus Pharmaceuticals, Inc. | EP | Method of treatment of attention deficit/hyperactivity disorder (ADHD) | 09812256.7 | 09/04/2009 |
| Supernus Pharmaceuticals, Inc. | CA | Method of treatment of CNS disorders | 2,782,314 | 12/02/2010 |
| Supernus Pharmaceuticals, Inc. | EP | Method of treatment of CNS disorders | 10835128.9 | 12/02/2010 |

| Grantor | Country | Patent | Application/ Patent No. | Filing Date |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | MX | Method of treatment of CNS disorders | MX/a/2012/006 276 | 12/02/2010 |
| Supernus Pharmaceuticals, Inc. | AU | Method of treatment of CNS disorders | 2010326016 | 12/02/2010 |
| Supernus Pharmaceuticals, Inc. | CA | A method of treatment of a neurological disorder | 2,767,029 | 06/30/2010 |
| Supernus Pharmaceuticals, Inc. | MX | A method of treatment of a neurological disorder | MX/a/2012/000 096 | 06/30/2010 |
| Supernus Pharmaceuticals, Inc. | AU | A method of treatment of a neurological disorder | 2010266285 | 06/30/2010 |
| Supernus Pharmaceuticals, Inc. | BR | A method of treatment of a neurological disorder | 018110052014 | 06/30/2010 |
| Supernus Pharmaceuticals, Inc. | CO | A method of treatment of a neurological disorder | 12018250 | 06/30/2010 |
| Supernus Pharmaceuticals, Inc. | EP | Stabilized formulations of CNS Compounds | 11763349.5 | 03/30/2011 |
| Supernus Pharmaceuticals, Inc. | CA | Stabilized formulations of CNS Compounds | 2,793,222 | 03/30/2011 |
| Supernus Pharmaceuticals, Inc. | MX | Stabilized formulations of CNS Compounds | MX/a/2012/010 829 | 03/30/2011 |
| Supernus Pharmaceuticals, Inc. | AU | Stabilized formulations of CNS Compounds | 2011235222 | 03/30/2011 |
| Supernus Pharmaceuticals, Inc. | JP | Stabilized formulations of CNS Compounds | 2013-502785 | 03/30/2011 |
| Supernus Pharmaceuticals, Inc. | EP | Formulations of mazindol | 11763348.7 | 03/30/2011 |
| Supernus Pharmaceuticals, Inc. | CA | Formulations of mazindol | 2,793,777 | 03/30/2011 |
| Supernus Pharmaceuticals, Inc. | MX | Formulations of mazindol | MX/a/2012/011 119 | 03/30/2011 |
| Supernus Pharmaceuticals, Inc. | AU | Formulations of mazindol | 2011235221 | 03/30/2011 |
| Supernus Pharmaceuticals, Inc. | JP | Formulations of mazindol | 2013-502784 | 03/30/2011 |
| Supernus Pharmaceuticals, Inc. | EP | Methods of producing viloxazine salts and novel polymorphs thereof | 11718804.5 | 04/12/2011 |
| Supernus Pharmaceuticals, Inc. | JP | Methods of producing viloxazine salts and novel polymorphs thereof | 2013-505028 | 04/12/2011 |
| Supernus Pharmaceuticals, Inc. | CA | Methods of producing viloxazine salts and novel polymorphs thereof | 2,795,408 | 04/12/2011 |

| Grantor | Country | Patent | Application/ Patent No. | Filing Date |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | MX | Methods of producing viloxazine salts and novel polymorphs thereof | MX/a/2012/011821 | 04/12/2011 |
| Supernus Pharmaceuticals, Inc. | AU | Methods of producing viloxazine salts and novel polymorphs thereof | 2011240773 | 04/12/2011 |
| Supernus Pharmaceuticals, Inc. | EP | Use of isoindoles for the treatment of neurobehavioral disorders | 09767450.1 | 06/04/2009 |
| Supernus Pharmaceuticals, Inc. | CA | Use of isoindoles for the treatment of neurobehavioral disorders | 2,728,234 | 06/04/2009 |
| Supernus Pharmaceuticals, Inc. | PCT | Formulations of viloxazine | PCT/US2013/025121 | 02/07/2013 |
| Supernus Pharmaceuticals, Inc. | PCT | Methods of producing molindone and its salts | PCT/US2013/32142 | 03/15/2013 |

## Patent Licenses

Licenses:

| Patent | Name and Address of Licensor |
|---|---|
| 6,897,212 | Afecta |
| 6,613,763 | Afecta |
| 12/477,665 | Afecta |

| Patent | Name and Address of Licensee |
|---|---|
| 2010189 | United Therapeutics |

Licenses:

| Patent | Name and Address of Licensor |
|---|---|
| 09767450.1 | Afecta |
| 2,728,234 | Afecta |

| Patent | Name and Address of Licensee |
|---|---|
| 2368556 | United Therapeutics |
| MX/a/2009/001711 | Stendhal |
| MX/a/2009/003911 | Stendhal |
| 287810 | Stendhal |
| | Daewoong |